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Background: Pseudomonas aeruginosa is an opportunistic bacterium that infects the airways of cystic fibrosis
patients, surfaces of surgical and burn wounds, and indwelling medical devices. Patients are prone to secondary
fungal infections, with Candida albicans being commonly co-isolated with P. aeruginosa. Both P. aeruginosa and
C. albicans are able to form extensive biofilms on the surfaces of mucosa and medical devices.
Objectives: To determine whether the presence of C. albicans enhances antibiotic tolerance of P. aeruginosa in a
dual-species biofilm.
Methods: Single- and dual-species biofilms were established in microtitre plates and the survival of each species
was measured following treatment with clinically relevant antibiotics. Scanning electron microscopy and
confocal microscopy were used to visualize biofilm structure.
Results: C. albicans enhances P. aeruginosa biofilm tolerance to meropenem at the clinically relevant concen-
tration of 5 mg/L. This effect is specific to biofilm cultures and is dependent upon C. albicans extracellular matrix
polysaccharides, mannan and glucan, with C. albicans cells deficient in glycosylation structures not enhancing
P. aeruginosa tolerance to meropenem.
Conclusions: We propose that fungal mannan and glucan secreted into the extracellular matrix of
P. aeruginosa/C. albicans dual-species biofilms play a central role in enhancing P. aeruginosa tolerance to mero-
penem, which has direct implications for the treatment of coinfected patients.
Introduction
The majority of infections in humans are polymicrobial in nature,
with common diseases no longer considered to be caused by a
single aetiological agent.1 The most prevalent polymicrobial infec-
tions include periodontitis, gastroenteritis, diabetic foot wounds,
burn wounds and biofilm-associated infections.1,2
The genetic disease, cystic fibrosis (CF), is characterized by
thickening of the mucus layer lining the endothelium of the re-
spiratory tract, which provides an ideal environment for microbial
colonization.3 Reduced mucociliary clearance enables these
microorganisms to persist and form polymicrobial biofilms on the
mucosa of the lower respiratory tract.1 The CF lung is a major site
of interaction between Pseudomonas aeruginosa and Candida albi-
cans.4,5 Around 70% of CF patients become chronically infected
with P. aeruginosa by the age of 30,6 with C. albicans isolated from
up to 75% of CF patients,7 although sputum samples are often
contaminated with microbes from the upper respiratory tract and
oral cavity.8 However, simultaneous colonization has been linked
to severer clinical outcomes,9,10 due to accelerated decline in lung
function and worsening of disease progression.10,11
Biofilms are structured communities of microbial cells ensnared
within a matrix of extracellular polymeric substances.12,13 Biofilms
are formed by bacterial and fungal species and an estimated
65%–80% of all microbial infections in humans are biofilm
related.2,14 This has important clinical implications as the MICs
of antimicrobials for biofilm cells can be 100–1000 times greater
than for planktonic cells.15,16 Antimicrobial resistance in
microorganisms poses an increasing challenge to public health
worldwide,17,18 making biofilms a particularly relevant topic of
research.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Previous work on interactions between P. aeruginosa and
C. albicans has focused predominantly on physical and molecular
interactions and their effects on growth, morphology and viru-
lence.19–24 However, little is known of how their interactions affect
antimicrobial drug efficacy. Studies on mono-species C. albicans
and P. aeruginosa biofilms have linked biofilm extracellular matrix
(ECM) material to antimicrobial drug inhibition. For example, the
fungal polysaccharide b-1,3-glucan sequesters the antifungal flu-
conazole,25 whilst the P. aeruginosa exopolysaccharides Pel and
Psl are implicated in the inhibition of various antibiotics, including
tobramycin.26 Therefore, a greater understanding of the impact
of this cross-kingdom interaction on antimicrobial tolerance is of
great clinical importance.
Meropenem is a first-line antibiotic for treating Pseudomonas
infections in the CF lung.27 Meropenem is a carbapenem b-lactam
that targets PBPs within Gram-negative bacteria, causing inhibition
of cell wall peptidoglycan synthesis, ultimately leading to osmotic
lysis of bacterial cells.28,29 Meropenem is administered intraven-
ously as a 15–30 min infusion of 1–2 g (adult dose), thrice daily for
2 weeks.30 When P. aeruginosa biofilms are treated with clinical
doses of meropenem, only bacteria at the biofilm peripheries are
killed, whilst cells closer to the base remain viable.31 In patients,
the meropenem concentration found in epithelial lining fluid 1 h
post-treatment is 5.3 mg/L,30 with the clinical breakpoint of
Pseudomonas being >8 mg/L.32 Therefore, slight deviations in tol-
erance of P. aeruginosa to meropenem could impede clearance
of the infection. Here, we observed that P. aeruginosa/C. albicans
dual-species biofilms displayed enhanced tolerance to merope-
nem. This protection was provided through active secretion of
fungal ECM components, specifically mannan and b-glucan.
Therefore, co-colonization of P. aeruginosa and C. albicans
within the CF lung may result in small reservoirs of protected
P. aeruginosa, which could survive antimicrobial treatment and
reseed the infection site.
Materials and methods
Strains and growth conditions
Strains of P. aeruginosa and Candida species used in this study are listed
in Table 1. P. aeruginosa strains were maintained on, and cultured in,
Miller-modified LB and C. albicans strains in yeast extract peptone dextrose
(YPD) medium. Both were grown at 37C, with aeration at 200 rpm.
Antimicrobials (from Sigma–Aldrich, UK) were used at the following concen-
trations (mg/L): meropenem, 0, 1, 2.5, 5 and 10; ceftazidime, 0 and 5;
ciprofloxacin, 0 and 0.05; tobramycin, 0 and 2; and fluconazole, 0, 250, 500,
750 and 1000.
Formation of dual-species biofilms
Biofilms were grown in 96-well plates as previously described.33 Briefly, cul-
tures were washed twice in PBS and P. aeruginosa cultures diluted to OD600
of 0.2 and Candida strains diluted to 1%106 cells/mL in Mueller–Hinton broth
(MHB) or DMEM supplemented with 1% L-glutamine. P. aeruginosa
(2.4%106) and Candida (1%105) cells were incubated statically in flat-
bottom 96-well plates for 2 h at 37C to enable attachment, then non-
adhered cells were removed and replaced with fresh medium. After 24h,
the medium was replaced with fresh medium containing the appropriate
amount of antimicrobial, or vehicle control, for an additional 18 h. To disrupt
biofilms, medium was replaced with 100lL of PBS containing 50 mg/L
DNase and incubated at 37C for 1 h. Biofilms were detached using a water
bath sonicator, serially diluted 1 in 10 in PBS and plated onto cetrimide
agar (to determine viable P. aeruginosa cfu) and YPD agar supplemented
with 100 mg/L tetracycline (to determine viable Candida cfu).
Experiments were performed with three technical and at least three
biological replicates.
Formation of P. aeruginosa biofilms in the presence of
dead C. albicans or ECM components
To inactivate C. albicans, stationary-phase cultures were washed with PBS
and cells either heat-killed at 100C in PBS for 1 h or fixed in 1 mL of 4% par-
aformaldehyde (PFA) at room temperature for 1 h. Cells were then washed
with PBS and diluted in MHB to 1%106 cells/mL. Subsequently, biofilms were
established and quantified as above.
Mono-species P. aeruginosa biofilms were established and grown for
24 h in MHB supplemented, at either 0 or 24 h, with 0.25 mg/mL glucan
(from Saccharomyces cerevisiae), laminarin (from Laminaria digitata), man-
nan (from S. cerevisiae) or chitosan. All polysaccharides were obtained from
Sigma–Aldrich, UK. After 24 h, medium was replaced with MHB containing
the appropriate amount of antibiotic and biofilms were subsequently incu-
bated and quantified as above.
Scanning electron microscopy of biofilms
Biofilms were prepared for scanning electron microscopy using a previously
published protocol34 with modifications. Single- and dual-species biofilms
were grown on cell culture-treated plastic coverslips (Thermo Fisher
Scientific) in 24-well plates for 24 h, after which the MHB medium was
replaced with MHB with or without 5 mg/L meropenem. At 48 h, coverslips
were washed twice with PBS and samples fixed in 2.5% glutaraldehyde in
0.1 M phosphate buffer for 1 h, at 4C. Samples were dehydrated using
increasing ethanol concentrations (50%, 70%, 90% and 100%) twice for
15 min each. Ethanol was replaced with liquid CO2 and heated up to the
critical point to dry the samples. Each coverslip was mounted on a stub and
sputter-coated with platinum. Scanning electron microscopy images were
captured using a Philips XL30 ESEM-FEG environmental scanning electron
microscope.
Confocal microscopy of biofilms
Single- and dual-species biofilms with or without 5 mg/L meropenem were
grown as above, scaled up to a final volume of 6 mL, in 6-well plates.
Medium was replaced with PBS containing 5 mg/L propidium iodide (stains
dead cells), 1 lM Syto 9 (dyes DNA) and 3 mg/L calcofluor white (stains
fungal cell wall chitin) and incubated at 4C in the dark for 1 h. Biofilms
were then fixed by adding 4% PFA, incubated at 4C in the dark for 1 h
and then washed twice with PBS. Confocal microscopy was performed
using a Leica SP8 system equipped with a Leica DM6 upright microscope,
a %40/0.80 objective and 402, 488 and 561 nm lasers. Biofilms were
imaged directly in wells with a water-dipping lens. Z-stack scans were
taken at two or three different areas within each well and processed
with Fiji and LASx software.
Planktonic assay
P. aeruginosa (2.4%107) and C. albicans (1%106) cells were added to 14 mL
vent-capped culture tubes in a final volume of 2 mL MHB. Cultures were
incubated for 3 h at 37C with aeration at 200 rpm; the appropriate amount
of antibiotic was added and cultures incubated for an additional 18 h.
Cultures were sonicated in a water bath sonicator and serially diluted and
plated for viable counts. Experiments were performed with three technical
and four biological replicates.
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Determination of P. aeruginosa susceptibility to
meropenem
MICs of meropenem were determined for P. aeruginosa strains according to
the standardized broth microdilution method using MHB.35 Concentrations
of meropenem used were 0, 1, 2, 4, 8, 16 and 32 mg/L. MICs were deter-
mined for P. aeruginosa strains using cells grown on LB agar and cells recov-
ered from biofilms. MICs were the lowest concentrations of meropenem
that caused no visible growth.
Statistical analysis
Statistical analyses were done using GraphPad Prism 8.0.0 software.
Data were analysed using two-way ANOVA and Holm–Sidak’s multiple
comparisons test.
Results
C. albicans increases the tolerance of P. aeruginosa to
meropenem in dual-species biofilms
To determine whether the presence of C. albicans within a
P. aeruginosa biofilm can enhance tolerance of P. aeruginosa to
meropenem, preformed mono-species (P. aeruginosa) and dual-
species (P. aeruginosa/C. albicans) biofilms were treated with
meropenem and P. aeruginosa survival quantified by viable counts.
Given that the concentration of meropenem in the lung immedi-
ately after administration is between 5 and 6 mg/L,30 this
drug concentration was the focus of the study. The viability of
P. aeruginosa mono-species biofilms was reduced to 25.35% when
treated with 5 mg/L meropenem, indicating P. aeruginosa biofilm
cells are susceptible to meropenem. Fewer P. aeruginosa cells
were recovered from dual-species biofilms, which is likely due to
nutrient competition. However, in the presence of C. albicans,
meropenem was non-effective against P. aeruginosa in both MHB
(Figure 1a) and DMEM (Figure S1, available as Supplementary data
at JAC Online), indicating that this inter–kingdom interaction
negatively affects meropenem efficacy.
To visualize the structure of the biofilms, samples were ana-
lysed by scanning electron microscopy and confocal microscopy.
Mono-species P. aeruginosa biofilms were significantly reduced in
the presence of meropenem, while in the meropenem-treated
dual-species biofilms, significant levels of P. aeruginosa colonized
Table 1. Bacterial and fungal strains used in this study
Strain Common name Genotype Reference/source
P. aeruginosa strains
ATCC 15692 PAO1 WT ATCC
Midlands 1 Midlands 1 clinical isolate 48
C. albicans strains
SC5314 SC5314 type strain 56
NGY152 NGY152 ura3D::imm34/ura3D::imm434; RPS1/rps1D::URA3 57
NGY355 pmr1D ura3D::imm434/ura3D::imm434; pmr1D::hisG/pmr1D::hisG; RPS10/
rps10D::URA3
58
NGY356 pmr1D! PMR1 ura3D::imm434/ura3D::imm434; pmr1D::hisG/pmr1D::hisG; RPS1/
rps1D::CIp10-PMR1
58
CDH15 mnn4D ura3D::imm434/ura3D::imm434; mnn4D::hisG/mnn4D::hisG; RPS10::URA3 57
CDH13 mnn4D!MNN4 ura3D::imm434/ura3D::imm434; mnn4D::hisG/mnn4D::hisG; RPS10::
[CIp10-MNN4-URA3]n
57
NGY582 mnn2D ura3D::imm434/ura3D::imm434; mnn2D::dpi200/mnn2D::dpi200;
RPS1/rps1D::CIp10
46
NGY583 mnn2D!MNN2 ura3D::imm434/ura3D::imm434; mnn2D::dpl200/mnn2D::dpl200;
RPS1/rps1D::CIp10-MNN2
46
NGY600 Dmnn2–26 ura3D::imm434/ura3D::imm434; mnn2D::dpl200/mnn2D::dpl200;
mnn22D::dpl200/mnn2D::dpl200; mnn23D::dpl200/mnn23D::dpl200;
mnn24D::dpl200/mnn24D::dpl200; mnn26D::dpl200/mnn26D::dpl200;
mnn21D::dpl200/mnn21D::dpl200; RPS1/rps1D::CIp10
46
NGY337 mnt1D/mnt2D ura3D::imm434/ura3D::imm434; mnt1D::hisG/mnt1D::hisG; mnt2D::
hisG/mnt2D::hisG; RPS10/rps10D::CIp10
55
NGY335 mnt1D/mnt2D
!MNT1
ura3D::imm434/ura3D::imm434; mnt1D::hisG/mnt1D::hisG; mnt2D::
hisG/mnt2D::hisG; RPS10/rps10D::CIp10-MNT1
55
Non-albicans Candida strains
WU284 C. dubliniensis WT 59
CAY676 C. tropicalis type strain ATCC
CLIB214 C. parapsilosis type strain 60
AM16/0701 C. krusei clinical isolate D. MacCallum, University of
Aberdeen, Scotland, UK
ATCC 2001 C. glabrata type strain ATCC
Candida enhances Pseudomonas antibiotic tolerance JAC
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Figure 1. C. albicans increases the tolerance of P. aeruginosa to meropenem in a dual-species biofilm. (a) Preformed 24 h biofilms were incubated for
18 h in MHB containing no antibiotic or 5 mg/L meropenem. Data are the mean ± SEM from five biological replicates. Data were analysed using
two-way ANOVA and Holm–Sidak’s multiple comparisons test (**P < 0.01). NS, not significant. (b) Scanning electron microscopy analysis of biofilms.
Meropenem treatment of mono-species P. aeruginosa biofilms results in death of bacterial cells, whilst the presence of C. albicans in the dual-species
biofilm enhances meropenem tolerance; the tight association of P. aeruginosa cells to fungal surfaces is visible. C. albicans alone is unaffected by
meropenem. (c) 3D reconstructions of biofilms from confocal z-stacks. Red indicates propidium iodide stain (dead cells), green indicates Syto 9 dye
(DNA) and blue indicates calcofluor white stain (chitin).
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the fungal hyphae (Figure 1b), confirming the cfu data. In agree-
ment with this, the biofilm thickness was lower in meropenem-
treated dual-species biofilms (Figure 1c and Figure S2), indicating
dense packing of bacterial cells against fungal hyphae, creating
a more compact biofilm structure. Therefore, the presence of
C. albicans enhances the tolerance of P. aeruginosa to meropenem.
To identify whether this dual-species interaction had any
impact on antifungal resistance, biofilms were treated with flucon-
azole. C. albicans cells in dual-species biofilms showed similar sus-
ceptibility levels to fluconazole as untreated controls at all tested
concentrations. Therefore, the presence of P. aeruginosa does
not affect the antifungal activity of fluconazole under the tested
conditions (Figure S3).
Meropenem tolerance is not maintained following
subculture of P. aeruginosa biofilm cells
The selective pressure from antibiotic use increases the likelihood
of cells developing resistance. The sessile nature and close proxim-
ity of biofilm cells promotes cell–cell interactions,36 increasing
horizontal gene transfer and mutation frequencies relative to
planktonic cells.37 Furthermore, the presence of C. albicans
increases P. aeruginosa mutation rates.20 To determine whether
the observed increase in meropenem tolerance of P. aeruginosa
was due to selection for resistance mutations, the meropenem
MICs for cells recovered from both P. aeruginosa mono- and dual-
species biofilms that had been treated with 5 mg/L meropenem,
or untreated, were determined by standard broth microdilution
MIC assay and compared with the MIC for the starter culture.
The MIC for P. aeruginosa under all tested conditions was 4 mg/L,
suggesting that P. aeruginosa cells recovered from treated biofilms
were not resistant to meropenem and, therefore, the observed
increased tolerance was unlikely due to selection for resistance
mutations.
Increased tolerance of P. aeruginosa to meropenem is
specific to dual-species biofilms
Enhanced survival of P. aeruginosa as a result of interactions with
C. albicans has previously been observed in planktonic cultures,
through inter–kingdom communication via secreted metabo-
lites.21 To determine whether the observed increase in merope-
nem tolerance of P. aeruginosa was specific to biofilms, P.
aeruginosa susceptibility to meropenem in the presence of C. albi-
cans was tested during planktonic growth. At all meropenem con-
centrations tested, there was no significant difference in P.
aeruginosa survival whether in the presence or absence of C. albi-
cans (Table 2), suggesting that C. albicans-mediated protection is
biofilm specific.
Increased P. aeruginosa tolerance to meropenem is
dependent on fungal viability
Production of biofilm ECM is an active process, involving secretion
of glycoproteins, polysaccharides, lipids and nucleic acids.2 To de-
termine whether the protective effect of C. albicans is mediated by
an active or passive mechanism, P. aeruginosa biofilms were
grown in the presence of either heat-killed C. albicans (disrupts the
fungal cell wall, denatures proteins and causes cell lysis) or by
fixing the C. albicans cells in 4% PFA (maintains cell structure).
However, in the presence of heat-killed or PFA-fixed C. albicans,
P. aeruginosa remained susceptible to meropenem (Figure 2),
suggesting that C. albicans actively protects P. aeruginosa from
meropenem.
Candida dubliniensis also enhances P. aeruginosa
meropenem tolerance in dual-species biofilms
Only a few species of the Candida genus are associated with dis-
ease in humans, including C. albicans, C. dubliniensis, Candida tropi-
calis, Candida parapsilosis, Candida krusei and Candida glabrata.38
Table 2. Increased P. aeruginosa meropenem tolerance in the presence
of C. albicans is biofilm specific
Meropenem
(mg/L)
Planktonic
culture
P. aeruginosa
count (cfu/mL),
mean ± SEM P
0 mono-species 4.00%109 ± 4.14%108 0.9040
co-culture 3.81%109 ± 2.78%108
1 mono-species 2.19%109 ± 1.63%108 0.3218
co-culture 1.64%109 ± 2.97%108
2.5 mono-species 7.36%108 ± 8.39%107 0.9650
co-culture 8.12%108 ± 1.57%108
5 mono-species 8.75%107 ± 2.82%107 0.9650
co-culture 1.56%108 ± 4.92%107
Planktonic cultures were grown for 3 h and subsequently incubated for
18 h in MHB containing 0, 1, 2.5 or 5 mg/L meropenem. Data are the
mean ± SEM from four biological replicates. Data were analysed using
two-way ANOVA and Holm–Sidak’s multiple comparisons test.
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Figure 2. Increased tolerance to meropenem is dependent on fungal
viability. Preformed 24 h biofilms were incubated for 18 h in MHB contain-
ing no antibiotic or 5 mg/L meropenem. Data are the mean ± SEM from
five biological replicates. Data were analysed using two-way ANOVA and
Holm–Sidak’s multiple comparisons test (**P <0.01). NS, not significant.
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To determine whether other Candida species can also protect
P. aeruginosa from meropenem, biofilms were grown in the pres-
ence of these clinically relevant non-albicans Candida (NAC) spe-
cies. Of the NAC species tested, only C. dubliniensis increased the
tolerance of P. aeruginosa to meropenem (Figure 3). C. dubliniensis
is phylogenetically most closely related to C. albicans,39 indicating
that C. albicans and C. dubliniensis may enhance P. aeruginosa
meropenem tolerance in a similar manner.
Fungal cell wall polysaccharides enhance P. aeruginosa
tolerance to meropenem
The secretion of ECM polymers, specifically polysaccharides, by
C. albicans biofilm cells is linked to increased antifungal resistance
of fungal biofilms.40,41 However, there is increasing evidence that
fungal ECM polysaccharides also contribute to antibiotic resistance
in dual-species fungal/bacterial biofilms.34,42,43 To determine
whether secreted fungal cell wall polymers play a role in protecting
P. aeruginosa, mono-species P. aeruginosa biofilms were grown in
the presence of purified fungal cell wall polysaccharides, including
glucan (a mix of b-1,3-glucan and b-1,6-glucan), laminarin (an iso-
form of b-1,3-glucan), mannan and chitosan (deacetylated chitin).
Both mannan and glucan enhanced tolerance of P. aeruginosa to
meropenem in biofilms (Figure 4a), but not in planktonic cultures
(Figure 4c). To determine whether mannan and glucan have
independent effects, P. aeruginosa biofilms were supplemented
with glucan and mannan in combination. However, no additive
effect was observed (Figure 4b). Mannan and glucan protected
P. aeruginosa when added to mature biofilms at the same time as
meropenem (Figure S4), suggesting that the polysaccharides may
sequester or inhibit the activity of the drug. Therefore, C. albicans
actively secretes mannan and/or glucan into the biofilm ECM,
which protects P. aeruginosa from meropenem.
C. albicans cell wall glycosylation is important for
protection against meropenem
To further investigate the role of fungal mannan in meropenem
tolerance, the ability of C. albicans cell wall glycosylation mutants
to protect P. aeruginosa was quantified. C. albicans has two major
forms of mannan, the extensively branched N-linked mannan and
the simple, linear O-linked mannan. Deletion of genes involved in
key glycosylation steps results in the incorporation of altered man-
nan epitopes in the cell wall (Figure 5a) and within the ECM.44–46 To
elucidate the role of these glycosylation structures in protecting
P. aeruginosa from meropenem, mutants defective in general pro-
tein glycosylation (pmr1D, ATPase required for transporting Ca2!
and Mn2! ions into the Golgi), N-mannan phosphomannan incorp-
oration (mnn4D), N-mannan side chain elaboration (mnn2D,
mnn2–26D) and O-mannan biosynthesis (mnt1D/mnt2D) were
tested for their ability to protect P. aeruginosa from meropenem.
Deletion of genes required for N-mannan biosynthesis (mnn4,
mnn2–26 and pmr1) reduced the ability of C. albicans to protect
P. aeruginosa from meropenem (Figure 5b and c). Scanning elec-
tron microscopy analysis showed very few bacterial cells surviving
meropenem treatment in dual-species biofilms with C. albicans
glycosylation mutants (Figure 5e) but bacteria that did survive
were closely adhered to the fungal cell surface, suggesting cell–
cell adherence may play a role in meropenem tolerance. In agree-
ment with this, deletion of genes involved in O-mannan biosyn-
thesis (mnt1/mnt2), which have previously been shown to be
involved in bacterial attachment to C. albicans,47 had the greatest
impact on P. aeruginosa protection (Figure 5d and e). This indicates
that protection of P. aeruginosa requires full elaboration of fungal
mannan.
C. albicans does not enhance P. aeruginosa tolerance to
other antibiotics
To determine whether the presence of C. albicans also affects toler-
ance of P. aeruginosa biofilm cells to other clinically relevant antibi-
otics, mono- and dual-species biofilms were treated with 5 mg/L
ceftazidime, 0.05 mg/L ciprofloxacin, 2 mg/L tobramycin or a com-
bination of 5 mg/L meropenem and 2 mg/L tobramycin. However,
the presence of C. albicans did not provide protection against these
antimicrobial treatments (Figure S5a and b), suggesting that the
mechanism by which C. albicans confers enhanced tolerance is likely
due to the chemical structure of meropenem.
C. albicans protects P. aeruginosa CF isolates from
meropenem
To explore the clinical relevance of the above findings, the ability of
C. albicans to increase meropenem tolerance of clinical CF isolates
was tested. Mono-species biofilms of the Midlands 1 CF isolate48
were susceptible to meropenem. However, P. aeruginosa survival
was unaffected during growth in a dual-species biofilm with
C. albicans (Figure 6), suggesting that in CF patients, co-
colonization with C. albicans may increase P. aeruginosa tolerance
to meropenem.
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Figure 3. C. dubliniensis also enhances tolerance of P. aeruginosa to
meropenem in dual-species biofilms. Preformed 24 h biofilms were
incubated for 18 h in MHB containing no antibiotic or 5 mg/L meropenem.
Data are the mean ± SEM from three biological replicates. Data were
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test (*P < 0.05). NS, not significant.
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Discussion
P. aeruginosa and C. albicans are commonly co-isolated from the
sputum of CF patients,20 where the thickened mucus layer lining
the endothelium of the lower respiratory tract provides an ideal
environment for biofilm formation.3,7 Chronic P. aeruginosa colon-
ization in the CF lung is correlated with increased likelihood of
C. albicans colonization, indicating a synergistic interaction that
leads to a greater decline in lung function.10,11 Here, we show that
C. albicans significantly enhanced P. aeruginosa biofilm tolerance
to 5 mg/L meropenem in both a laboratory strain and a CF isolate.
Although the protective effect was relatively small (<1 log10
change in P. aeruginosa cfu/mL), this may still have clinical rele-
vance. For example, the clinical breakpoint of P. aeruginosa for
meropenem is >8 mg/L;32 this increased tolerance could push the
required meropenem concentration over the clinical breakpoint,
categorizing the infection as meropenem resistant. This has direct
implications for treatment of CF patients who present with coinfec-
tion. Standard doses of meropenem may become insufficient
for treating P. aeruginosa infection, with combination antibiotic/
antifungal therapy being a potentially more effective therapeutic
option.
The protective effect of C. albicans was biofilm specific and
dependent upon fungal ECM components. This is consistent with
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Figure 4. Mannan and glucan enhance P. aeruginosa biofilm tolerance to meropenem. Fungal polysaccharides were used at a final concentration of
0.25 mg/mL. (a) Mannan and glucan enhance P. aeruginosa biofilm tolerance to 5 mg/L meropenem. Preformed 24 h biofilms were incubated for 18 h
in MHB containing no antibiotic or 5 mg/L meropenem. Data are the mean ± SEM from six biological replicates. (b) The effects of mannan and glucan
are not additive. (c) Enhanced meropenem tolerance from mannan and glucan is biofilm specific. Planktonic cultures supplemented with exogenous
mannan and/or glucan were grown for 3 h and subsequently incubated for 18 h in MHB containing 5 mg/L meropenem. Data are the mean ± SEM
from three biological replicates. Data were analysed using two-way ANOVA and Holm–Sidak’s multiple comparisons test (*P < 0.05, **P < 0.01 and
****P < 0.0001). NS, not significant.
Candida enhances Pseudomonas antibiotic tolerance JAC
7 of 11
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/advance-article-abstract/doi/10.1093/jac/dkz514/5684825 by U
niversity of Birm
ingham
 user on 03 January 2020
1010
Phosphomannan N-mannan O-mannan
Ser/Thr
Mon
o-sp
ecie
s
+ NG
Y15
2
pmr1D
pmr1D
NH
Asn-X-Ser/Thr
N-acetylglucosamine
β-1,4-mannose
β-1,2-mannose
a-mannosea-1,2-mannose Biofilm
a-1,3-mannose
a-1,6-mannose
Phosphate (PO4  
2–)
mnt1D/mnt2D
mnn4D
mnn2D
mnn2–26D
n
NS
Biofilm Biofilm
No antibiotic 5 mg/L meropenem
No antibiotic 5 mg/L meropenem
No antibiotic
PAO1 +
NGY152
N
o 
an
tib
io
tic
5 
m
g/
L 
m
er
op
en
em
PAO1 +
mnn4Δ
PAO1 +
mnn4Δ + MNN4
PAO1 +
mnt1Δ/mnt2D
PAO1 +
mnt1Δ/mnt2D + MNT1
5 mg/L meropenem
NS NS
NS**** ** *** **NS NS NS
NS******** **** ****
109
P.
 a
er
ug
in
os
a 
co
un
t 
(c
fu
/m
L)
108
107
Mon
o-sp
ecie
s
Mono
-spec
ies
+ SC
531
4
+ NGY
152
+ N
GY1
52
+ m
nn2
–26
D
+ m
nn4
D
+ pm
r1D
+ m
nn2
D
+ m
nn4
D+ M
NN4
+ m
nn2
D+ M
NN2
+ pm
r1D+
 PM
R1
+ mn
t1D /m
nt2D
+ mn
t1D /m
nt2D+
 MNT1
1010
1010
109
108
P.
 a
er
ug
in
os
a 
co
un
t 
(c
fu
/m
L)
107
109
P.
 a
er
ug
in
os
a 
co
un
t 
(c
fu
/m
L)
108
107
(a) (b)
(c)
(e)
(d)
Figure 5. C. albicans cell wall glycosylation is important for protection against meropenem. (a) Schematic diagram representing the structure of N-mannan
(including phosphomannan) and O-mannan of C. albicans.44,46 The points of truncation of the mutants used in this study are indicated by arrows. The
pmr1D mutant causes loss of a Golgi Ca2!/Mn2!-ATPase, affecting numerous mannosyltransferases, so the extent of truncation of the a-1,6-mannose
backbone is variable.44,45 (b) N-mannan glycosylation is important for protection against meropenem. Preformed 24 h biofilms were incubated for 18 h in
MHB containing no antibiotic or 5 mg/L meropenem. The N-mannan glycosylation mutants (mnn4D, pmr1D or mnn2D) inhibit the ability of C. albicans to
protect P. aeruginosa. Tolerance to meropenem is restored in reconstituted control strains. (c) The mnn2–26D sextuple mutant, in which only the unsubsti-
tuted a-1,6-mannose backbone of N-mannan remains, inhibits the ability of C. albicans to protect P. aeruginosa. (d) O-mannan glycosylation is important
for protection against meropenem. The mnt1D/mnt2D double mutant inhibits the ability of C. albicans to protect P. aeruginosa. Meropenem tolerance
is restored when MNT1 is reconstituted. Data are the mean ± SEM from three biological replicates. Data were analysed using two-way ANOVA and
Holm–Sidak’s multiple comparisons test (**P < 0.01, ***P < 0.001 and ****P < 0.0001 in panels b, c and d). NS, not significant. (e) Scanning electron microscopy
analysis of biofilms. Deletion of genes required for fungal N-mannan biosynthesis (mnn4) or O-mannan biosynthesis (mnt1/mnt2) reduced the ability of C.
albicans to protect P. aeruginosa from meropenem, as indicated by the reduction in the number of bacterial cells following meropenem treatment; the ma-
jority of surviving bacteria are in close contact with fungal cells. When the genes (MNN4 or MNT1) are reconstituted, the protective effect is restored, as evi-
denced by the abundance of P. aeruginosa cells coating the fungi in the meropenem-treated samples.
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other reports where C. albicans ECM components have been shown
to provide protection against ofloxacin and vancomycin in dual-
species biofilms with Escherichia coli and Staphylococcus aureus,
respectively.42,43 However, in contrast to these studies, where
C. albicans ECM components provide protection against a range
of antimicrobials, C. albicans ECM components only increased
P. aeruginosa tolerance to meropenem. This suggests that the
mechanism by which C. albicans ECM components enhance
meropenem tolerance may be different to those proposed for
other antibiotics. Considering the effect was not seen for other
b-lactams (i.e. ceftazidime) this suggests the protective mechan-
ism may depend on chemical structure or ability to bind mannan
or b-glucan, rather than the mode of action.
Previously, mannan and b-glucan have been shown to bind
and sequester antimicrobials, limiting their diffusion through
biofilms.43 Therefore, it is possible that the actual concentration of
meropenem within dual-species biofilms is significantly lower.
Similar interactions have been observed in dual-species biofilms
where Streptococcus mutans exopolysaccharides bind and se-
quester fluconazole, reducing its efficacy against C. albicans.49
Alternatively, mannans or glucans may coat bacterial cells, provid-
ing a physical barrier that impedes drug permeation, supporting
the proposed mechanism by which S. aureus is protected from
vancomycin.42
Although C. albicans remains clinically the most commonly
isolated Candida species, the prevalence of NAC species is increas-
ing.50 C. dubliniensis was the only NAC species that protected
P. aeruginosa from meropenem. This finding is of clinical relevance
as, although less common than C. albicans, the prevalence of
C. dubliniensis within CF patients ranges from 2.6% to 39.0%
and there are cases of C. dubliniensis being co-isolated with
P. aeruginosa from the lower respiratory tracts of CF patients.51
C. dubliniensis is the most closely related NAC species to C. albicans
and, as a result, their biofilms are structurally similar,38,39 with net-
works of yeast and hyphal cells embedded in a comparable ECM.52
Although the other NAC species produce biofilms, the composition
of their ECM is considerably different53,54 and their biofilms lack
hyphae, which are important for bacterial attachment. Scanning
electron microscopy confirmed that most bacteria in the treated
dual-species biofilms were attached to fungal hyphae, suggesting
that this interaction is important for protection. This hypothesis is
supported by the fact that removal of O-mannan, which is required
for bacterial binding,47,55 reduced the ability of C. albicans to pro-
tect P. aeruginosa. However, given that purified carbohydrates
were able to provide similar protection to C. albicans, it would
suggest that ECM composition is the major contributing factor
providing antimicrobial protection.
In conclusion, secreted C. albicans ECM polysaccharides protect
P. aeruginosa by reducing the efficacy of meropenem. Clinically,
this could result in persistent bacterial infection due to pockets of
protected cells, which may then acquire true resistance as a result
of continued exposure to subMIC concentrations of antibiotics.
This highlights the importance of early diagnosis of dual-species
biofilm infections, so that more efficacious therapeutic options,
such as combination antibiotic/antifungal therapy, can be
considered.
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